Fundraising Fox

Contineum Therapeutics

NASDAQ: CTNM

Founded 2017 · 59 employees on LinkedIn · 6 known investors

Contineum is a biopharmaceutical company developing small molecule drug candidates to treat inflammatory and fibrotic diseases by modulating critical disease pathways. The company is advancing multiple candidates into clinical trials, with a focus on diseases of high unmet medical need.

BiotechHealthtech

Founders & leadership

CSCarmine Stengone
Carmine StengoneinPresident and Chief Executive Officer

Investors · 6

Hadean VenturesOslo
Red Tree VentureSan Diego
Samsara BioCapitalPalo Alto
Casdin CapitalreportedNew York
Franklin TempletonreportedSan Mateo
Sectoral Asset ManagementreportedMontreal

Competitors · 1

by search overlap
Bioworld30 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Contineum Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Contineum Therapeutics schedules a Sept. 15 fireside chat at 5:35 p.m.stocktitan.net · Aug 2026Contineum Therapeutics, Inc. Q1 2026 Financial Report: Earnings, Clinical Pipeline Progress, and Forward-Looking Statements 14 – Minichartminichart.com.sg · May 2026Contineum IPO Nets $110M - San Diego Business Journalsdbj.com · Apr 2024

Frequently asked questions

What does Contineum Therapeutics do?
Contineum is a biopharmaceutical company developing small molecule drug candidates to treat inflammatory and fibrotic diseases by modulating critical disease pathways. The company is advancing multiple candidates into clinical trials, with a focus on diseases of high unmet medical need.
Who are Contineum Therapeutics's investors?
Contineum Therapeutics's investors include Hadean Ventures, Red Tree Venture, Samsara BioCapital, Casdin Capital, Franklin Templeton, Sectoral Asset Management.